New research shows U.S. pays premium prices for drugs; Finds Profits More than $30billion higher than R&D spending

Dr. Peter B. Bach and his team at Memorial Sloan Kettering Cancer Center compare U.S. prices of the 20 top-selling drugs globally to their counterparts in Canada, Denmark, Ireland, and the United Kingdom. The results show, on average, list prices in the other developed countries are only 43% of U.S. net drug prices. To put that in perspective, in 2015, the U.S. net prices were $112B higher than the other countries’ list prices, while the companies spent only $77B of that amount on global R&D.

Read the full article on the Health Affairs Blog.